Overview
In what was a good quarter overall for the publicly traded hospital operators, the midsized urban markets operator Ardent Health bore the brunt of “persistent industry-wide cost pressures, particularly those around professional fees and payer denials.” $ARDT ( 0.0% ) stock was down nearly 36%, trading significantly lower than that of its peers who shared similar sentiments on their calls
Ardent’s strategy is to be number 1 and 2 in growing “midsized urban markets.” It seems like a logical thesis, and I’m interested in tracking their performance over the long run as their peers largely focus on different markets. For this quarter, however, I’m curious if some derivative of this strategy caused professional fee growth and payer denials to hit them harder.
Quarter highlights:
Total revenue was $1.58 billion, 8.8% growth YoY
Net loss attributable to Ardent Health was $23m
Adjusted EBITDA was $143 million, 46.3% growth YoY
Admissions grew 5.8% YoY and Adjusted Admissions growth was 2.9% YoY
Net patient service revenue per adjusted admission growth was 5.8% YoY
Revised 2025 guidance:
Reaffirmed total revenue between $6,200 and $6,450 million
Revised Adjusted EBITDA down between $530 and $555 million
Links:
Key Metrics
Operating Performance Summary
Revised 2025 Financial Guidance
Earnings Call Discussion:
Here are a few key takeaways from the earnings discussion:
Join the Health Tech Nerds Community to access.
Join thousands of other innovators in healthcare accelerating their learning in healthcare.
Join the Health Tech Nerds CommunityA community membership gets you:
- Private Slack Community: Exchange ideas, lessons learned and insights with your peers in real time.
- Exclusive insights & expert content: Access deep dives, case studies, and curated wisdom, plus live sessions with industry leaders.
- Networking made easy: Get curated matches, connect through the member directory, and join or host local meetups.
- Proven tools & resources: Save time with research, templates, and community-sourced solutions.